Two Sigma Investments LP Has $679,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

Two Sigma Investments LP trimmed its stake in Celcuity Inc. (NASDAQ:CELC - Free Report) by 61.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,838 shares of the company's stock after selling 80,969 shares during the quarter. Two Sigma Investments LP owned about 0.14% of Celcuity worth $679,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of CELC. Baker BROS. Advisors LP lifted its stake in shares of Celcuity by 42.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company's stock valued at $35,062,000 after buying an additional 803,575 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Celcuity by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock valued at $21,624,000 after buying an additional 24,429 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Celcuity by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock valued at $9,065,000 after buying an additional 62,003 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Celcuity in the fourth quarter valued at $8,468,000. Finally, Artisan Partners Limited Partnership lifted its stake in shares of Celcuity by 18.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 491,507 shares of the company's stock valued at $6,434,000 after buying an additional 75,830 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $29.00 price target on shares of Celcuity in a research report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Monday, May 19th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Celcuity currently has an average rating of "Buy" and an average target price of $30.80.

Celcuity Trading Up 10.8%

Shares of CELC opened at $13.05 on Friday. The firm has a market cap of $494.15 million, a price-to-earnings ratio of -5.00 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $19.77. The firm has a 50 day moving average price of $10.39 and a 200-day moving average price of $11.30.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. As a group, equities research analysts forecast that Celcuity Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.